LB Pharmaceuticals Inc Common Stock

LBRXNASDAQHealthcare● Active

$28.98

+$0.45(+1.59%)

Market Cap$831189891

P/E Ratio—

52W High$33.47

52W Low$13.36

Avg Volume236K

Open$28.84

Beta0.71

Earnings Financials Revenue

LB Pharmaceuticals Inc Common Stock (LBRX) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

LBRX · earnings · updated Jun 8, 2026

Latest Earnings

Q2 FY2026Report Date: May 12, 2026

EPS Actual

-$0.67

Est. -$0.75 · +10.7%

Revenue

—

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 12, 2026

After Market Close

▲ Beat EPS✓ 2-Quarter EPS Beat Streak

LBRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Rev. $0.00B

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

Rev. Est.$0.00B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 11, 2026	-$0.84	—	—	—	—	—
▲ Q2 FY2026	May 12, 2026	-$0.75	-$0.67	+10.7%	—	—	—
— Q1 FY2026	Mar 26, 2026	-$0.45	-$0.45	+0.0%	—	—	—
▼ Q4 FY2025	Nov 6, 2025	-$0.57	-$0.61	-7.0%	—	—	—

Q3 FY2026

Aug 11, 2026

EPS Actual

—

EPS Est.

-$0.84

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 12, 2026Beat

EPS Actual

-$0.67

EPS Est.

-$0.75

EPS Surpr.

+10.7%

Revenue

—

Q1 FY2026

Mar 26, 2026

EPS Actual

-$0.45

EPS Est.

-$0.45

EPS Surpr.

+0.0%

Revenue

—

Q4 FY2025

Nov 6, 2025Miss

EPS Actual

-$0.61

EPS Est.

-$0.57

EPS Surpr.

-7.0%

Revenue

—

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2027	$-1.23	$-1.23	$-1.23	2
Q3 FY2027	$-1.20	$-1.20	$-1.20	1
Q2 FY2027	$-1.00	$-1.00	$-1.00	1
Q1 FY2027	$-1.12	$-1.12	$-1.12	2
Q4 FY2026	$-1.06	$-1.06	$-1.06	2
Q3 FY2026	$-0.98	$-0.95	$-0.86	4

Revenue Estimates

Period	Low	Consensus	High
Q4 FY2027	$0.0B	$0.0B	$0.0B
Q3 FY2027	$0.0B	$0.0B	$0.0B
Q2 FY2027	$0.0B	$0.0B	$0.0B
Q1 FY2027	$0.0B	$0.0B	$0.0B
Q4 FY2026	$0.0B	$0.0B	$0.0B
Q3 FY2026	$0.0B	$0.0B	$0.0B

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q2 FY2026	May 12, 2026	+10.7%	$32.70	$31.13	-4.80%
▲ Q1 FY2026	Mar 26, 2026	+0.0%	$24.21	$24.53	+1.32%
▼ Q4 FY2025	Nov 6, 2025	-7.0%	$16.20	$15.51	-4.26%

Q2 FY2026-4.80%

Report Date

May 12, 2026

EPS Beat/Miss

+10.7%

Price Before

$32.70

Price After

$31.13

Q1 FY2026+1.32%

Report Date

Mar 26, 2026

EPS Beat/Miss

+0.0%

Price Before

$24.21

Price After

$24.53

Q4 FY2025-4.26%

Report Date

Nov 6, 2025

EPS Beat/Miss

-7.0%

Price Before

$16.20

Price After

$15.51

Avg Beat Reaction-1.74%

Avg Miss Reaction-4.26%

Beat Rate2 / 3 quarters

Largest Move-4.80% (Q2 FY2026)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

LB Pharmaceuticals Inc Common Stock (LBRX) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.67 — beating the analyst consensus of $-0.75 by +10.7%. LBRX has beaten EPS estimates for 2 consecutive quarters. The next LBRX earnings date is expected around September 1, 2026.

Each quarter, investors track LBRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LBRX revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

LBRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

LBRX earnings · 5 questions

LB Pharmaceuticals Inc Common Stock's next earnings report is expected around September 1, 2026. LBRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LBRX historically reports after market close (AMC).

LBRX earnings datewhen is LBRX earningsLBRX next earnings datewhen does LBRX report earningsLBRX earnings calendar

▸ Source: FMP · LB Pharmaceuticals Inc Common Stock SEC filings · US GAAP · LB Pharmaceuticals Inc Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026